Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems Regains Compliance with Nasdaq Listing Requirement

NEW YORK — T2 Biosystems said on Tuesday that it has received notice that it has regained compliance with the Nasdaq's minimum bid price requirement.

About a year ago, the Lexington, Massachusetts-based infectious disease test maker was informed by the Nasdaq that its stock did not meet the exchange's required closing bid price of $1 for a period of 30 consecutive business days.

Following a recent 1-for-50 reverse stock split, T2's shares were trading at or above the $1 mark for at least 10 consecutive trading days, settling the issue. During early Tuesday morning trading, shares of T2 were up $.06 at $1.91.

Earlier this month, investment bank Canaccord Genuity cut its rating on T2 to Hold from Buy, citing low revenues and slower-than-expected product development.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.